The first phase I trial will investigate the efficacy of XL844 in patients with chronic lymphocytic leukemia, the second trial for a compound labeled XL184 will be conducted in patients with solid tumors for whom there are no available therapies.
In addition, a repeat-dose phase I clinical trial has been initiated for a third compound, XL784, in healthy volunteers. This study marks the preparation for a phase II program to test the efficacy of the drug in patients with renal failure.
The company has brought a total of eight compounds into clinical development, the most advanced of which are nearing completion of phase I testing. It is anticipated that these compounds will progress into phase II trials by the end of the year.
“We anticipate soon having four compounds in phase II or later, and expect to have substantial insight into all of these compounds within a reasonable time frame,” said Dr George Scangos, president and chief executive officer of Exelixis.